论文部分内容阅读
目的研究葵花护肝片联合厄贝沙坦片治疗高血压及预防药物性肝损伤的临床效果。方法 108例高血压患者(排除因其他病因所导致的肝损伤患者),随机分为对照组和观察组,各54例。对照组口服厄贝沙坦片进行治疗,观察组给予厄贝沙坦片的同时服用葵花护肝片进行治疗。治疗8周后比较两组血压情况及肝脏受损率。结果对照组血压下降情况:收缩压(32.78±12.96)mm Hg;舒张压(14.17±11.11)mm Hg,观察组血压下降情况:收缩压(30.22±13.14)mm Hg(1 mm Hg=0.133 k Pa);舒张压(13.14±9.27)mm Hg,两组比较差异无统计学意义(P>0.05)。对照组总有效率为94.4%,观察组总有效率为96.3%,两组比较差异无统计学意义(P>0.05)。对照组出现9例转氨酶升高患者,占16.7%,其中3例出现口渴、恶心、呕吐。观察组未出现转氨酶升高患者,并且未出现其他不良反应。两组肝损伤发生率比较差异具有统计学意义(P<0.05)。结论服用厄贝沙坦治疗高血压过程中,联合葵花护肝片治疗可有效预防药物性肝损伤,可在临床推广应用。
Objective To study the clinical efficacy of sunflower liver tablet combined with irbesartan tablets in the treatment of hypertension and drug-induced liver injury. Methods A total of 108 hypertensive patients (excluding patients with liver injury caused by other causes) were randomly divided into control group and observation group, with 54 cases in each group. The control group was given oral irbesartan tablets for treatment. The observation group was given irbesartan tablets while taking sunflower liver tablets for treatment. Eight weeks after treatment, blood pressure and liver damage were compared between the two groups. Results The decrease of blood pressure in the control group was: systolic pressure (32.78 ± 12.96) mm Hg, diastolic pressure (14.17 ± 11.11) mm Hg, systolic blood pressure (30.22 ± 13.14) mm Hg ); Diastolic blood pressure (13.14 ± 9.27) mm Hg, no significant difference between the two groups (P> 0.05). The total effective rate was 94.4% in the control group, and the total effective rate in the observation group was 96.3%. There was no significant difference between the two groups (P> 0.05). Nine patients with elevated aminotransferase in the control group, accounting for 16.7%, of which 3 cases of thirst, nausea and vomiting. The observation group did not appear elevated transaminases patients, and no other adverse reactions. The incidence of liver injury between the two groups was statistically significant (P <0.05). Conclusion Irbesartan in the treatment of hypertension, the combination of liver protection Liver tablets can effectively prevent drug-induced liver injury, which can be popularized in clinical application.